Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nbt.2202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The conclusions of the European Food Safety Authority (EFSA) following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State, the Netherlands, and co-rapporteur Member State, France, for the pesticide active substance spinosad and the assessment of applications for maximum residue levels (MRLs) are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of spinosad as insecticide on bulb/dry onions, maize (fodder and grain), sweet corn, grapes (table and wine), lettuce, potato, aubergine, pepper and tomato.
View Article and Find Full Text PDFLarval development and parasitism of emerald ash borer (Agrilus planipennis) in Oregon ash (Fraxinus latifolia) and European olive (Olea europaea): implications for the West Coast invasion.
J Econ Entomol
January 2025
Department of Entomology and Wildlife Ecology, University of Delaware, Newark, DE, USA.
The invasive emerald ash borer (Agrilus planipennis Fairmaire) (EAB) has been devastating North American ash (Fraxinus spp.) resources for over 2 decades. In its native range, EAB attacks and kills primarily stressed ash trees.
View Article and Find Full Text PDFThe efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma.
BMC Cancer
January 2025
Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, Shandong Province, China.
Purpose: To evaluate the efficacy and safety of induction chemotherapy combined with programmed death protein 1 (PD-1) inhibitor (sintilimab) followed by concurrent chemoradiotherapy (CCRT) plus sintilimab, and subsequent maintenance with sintilimab (IC-ICCRT-IO) for patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a retrospective study.
Methods: Data from patients with histologically confirmed, locally advanced, inoperable ESCC who received IC-ICCRT-IO were retrospectively analyzed. Treatment effects were evaluated after 2 cycles of induction therapy and after CCRT by contrast-enhanced CT scans and esophagograms, followed by subsequent evaluations every 3 months post-treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!